Abbott to Spin Off Nutrition Business Amid Sales Growth Cut

• Abbott Laboratories is cutting its 2026 sales growth forecast.
• The company plans to spin off its nutrition business into a standalone public company.
• The nutrition unit, central to baby formula lawsuits, is expected to generate $8.5 billion in annual sales.
• Abbott's stock fell following the announcement of earnings and the spin-off plan.
• Despite the spin-off, Abbott Labs' solid financial performance signals long-term EPS growth and dividend safety.